Seattle General Hospital and School for Nurses was a hospital and nursing school in the U.S. state of Washington. It was located at 909 Fifth Avenue in Seattle. The hospital was originally established in 1895 and reopened in a new building in 1900. In 1980, it merged with Swedish Medical Center.

During the past decade, Seattle Children's Hospital conducted 451 clinical trials. In the 10-year time frame, 451 clinical trials started and 229 clinical trials were completed, i.e. on average, 50.8% percent of trials that started reached the finish line to date. In the past 5 years, 150 clinical trials started and 112 clinical trials were completed. i.e. 74.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Seattle Children's Hospital" #1 sponsor was "Children's Oncology Group" with 188 trials, followed by "Seattle Children's Hospital" with 106 trials sponsored, "National Cancer Institute (NCI)" with 101 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 35 trials sponsored and "Children's Hospital of Philadelphia" with 35 trials sponsored. Other sponsors include 537 different institutions and companies that sponsored additional 237 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Seattle Children's Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 223 trials as a collaborator, "Seattle Children's Hospital" with 50 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 28 trials as a collaborator, "Cystic Fibrosis Foundation" with 24 trials as a collaborator and "University of Washington" with 22 trials as a collaborator. Other collaborators include 928 different institutions and companies that were collaborators in the rest 408 trials.

According to Clinical.Site data, the most researched conditions in "Seattle Children's Hospital" are "Neuroblastoma" (50 trials), "Cystic Fibrosis" (47 trials), "Leukemia" (41 trials), "Recurrent Neuroblastoma" (33 trials) and "Unspecified Childhood Solid Tumor, Protocol Specific" (31 trials). Many other conditions were trialed in "Seattle Children's Hospital" in a lesser frequency.

Most popular intervention types in "Seattle Children's Hospital" are "Drug" (611 trials), "Other" (225 trials), "Biological" (153 trials), "Procedure" (123 trials) and "Radiation" (90 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (86 trials), "Placebo" (65 trials), "Cyclophosphamide" (54 trials), "Pharmacological Study" (45 trials) and "cyclophosphamide" (42 trials). Other intervention names were less common.

The vast majority of trials in "Seattle Children's Hospital" are 954 trials for "All" genders, 20 trials for "Male" genders and 14 trials for "Female" genders.

Currently, there are 372 active trials in "Seattle Children's Hospital". 4 are not yet recruiting, 188 are recruiting, 169 are Active, not recruiting, and 11 are Enrolling by invitation. In total, there were 523 completed trials in Seattle Children's Hospital, 3 suspended trials, and 50 terminated clinical trials to date.

Out of the total trials that were conducted in Seattle Children's Hospital, 209 "Phase 1" clinical trials were conducted, 264 "Phase 2" clinical trials and 232 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 136 trials that are defined as “Not Applicable".

Seattle Children's Hospital has several departments that took part in Clinical trials: "Seattle CHildrens Research Institute" - 65 trials, "Seattle Children's Research Institute CRS" - 11 trials, "Seattle Children's Hospital CRS" - 8 trials, "Seattle Children's Hospital - Infectious Diseases" - 7 trials, "CFF Care Center & Pediatric Program Seattle Children's Hospital" - 4 trials, "Odessa Brown Children's Clinic" - 2 trials, "Seattle Children's Hospital Emergency Department" - 2 trials, "Seattle Children's Hospital - Childhood Cancer and Blood Disorders" - 2 trials